St. Jude Medical (NYSE: STJ ) reported earnings Wednesday. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), St. Jude Medical met expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped slightly and GAAP earnings per share grew.
Gross margins dropped, operating margins contracted, and net margins increased.
St. Jude Medical notched revenue of $1.41 billion. The 23 analysts polled by S&P Capital IQ anticipated net sales of $1.43 billion on the same basis. GAAP reported sales were 2.5% lower than the prior-year quarter's $1.45 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.88. The 26 earnings estimates compiled by S&P Capital IQ anticipated $0.87 per share. GAAP EPS of $0.77 for Q2 were 6.9% higher than the prior-year quarter's $0.72 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 74.0%, 50 basis points worse than the prior-year quarter. Operating margin was 26.7%, 10 basis points worse than the prior-year quarter. Net margin was 17.3%, 60 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $1.37 billion. On the bottom line, the average EPS estimate is $0.82.
Next year's average estimate for revenue is $5.63 billion. The average EPS estimate is $3.45.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on St. Jude Medical is outperform, with an average price target of $46.65.
More Expert Advice from The Motley Fool
The Motley Fool's chief investment officer has selected his No. 1 stock for the next year. Find out which stock in our brand-new free report: "The Motley Fool's Top Stock for 2013
." I invite you to take a copy, free for a limited time. Just click here
to access the report and find out the name of this under-the-radar company.